We recently published a list of 10 Best Medical Stocks to Buy Now. In this article, we are going to take a look at where ...

Detailed data from a Phase 2b/3 study of Merck’s treatment clesrovimab should support the company’s efforts to win approval by the 2025-2026 season.

While you may think of healthcare as only covering human health, animal and pet health is also a growing sector. Click to read.

Merck announces positive results from Phase 2b/3 and interim Phase 3 trials of a monoclonal antibody designed to protect infants from RSV.

New data released by Merck suggests AstraZeneca and Sanofi’s Beyfortus, the monoclonal antibody injection that protects ...

Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some ...

Clesrovimab (MK-1654), an Investigational RSV Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease and ...

We recently compiled a list of 10 Most Promising Long-Term Stocks According to Hedge Funds. In this article, we will look at ...

We recently published a list of 10 Most Promising Low-Cost Stocks According to Hedge Funds. In this article, we are going to ...

On Oct. 1 and 2, the American Chemical Society held its 21st annual Pharma Leaders Conference, hosted this year at the Merck & Co. campus in Rahway, New Jersey. Leaders in medicinal chemistry from ...

German science and technology group Merck is open to more acquisitions for its Life Science business after announcing in May ...

North Carolina Agricultural and Technical State University and Merck (NYSE: MRK), known as MSD outside of the United States ...